Esperion Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/17/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. TLT
7. AMZN
8. LEN
9. APO
10. ON

Go back to Esperion Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update

Esperion Therapeutics (ESPR) Tops Q4 EPS by 50c

February 22, 2022 7:14 AM EST

Esperion Therapeutics (NASDAQ: ESPR) reported Q4 EPS of ($1.77), $0.50 better than the analyst estimate of ($2.27). Revenue for the quarter came in at $15.4 million versus the consensus estimate of $14.48 million.

2022 Financial Outlook:

Research and Development expenses for the full year 2022 are expected to be... More